Funding Opportunity RFA-DA-18-022 from the NIH Guide for Grants and Contracts. This FOA supports highly innovative R01 applications on HIV/AIDS and drug abuse and complements the Avant-Garde Award Program for HIV/AIDS and Drug Use Research and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS. The Avant-Garde award supports individuals who conduct high-risk, high-reward research and does not require a detailed research plan. The Avenir award is similar to the Avant-Garde award but focuses on support for early stage investigators. Applications submitted under this FOA are required to have a detailed research plan and preliminary data. This FOA focuses on innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among substance abusers. The nexus with drug abuse should be clearly described. This FOA is open to both individual researchers and research teams and is not limited to any one area of research on HIV and substance use, but all studies must focus on NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html.

Funding Opportunity PAR-18-714 from the NIH Guide for Grants and Contracts. The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years.

Notice NOT-AT-18-010 from the NIH Guide for Grants and Contracts

Notice NOT-AT-18-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-700 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences.

Notice NOT-AR-18-020 from the NIH Guide for Grants and Contracts

Notice NOT-AR-18-019 from the NIH Guide for Grants and Contracts

Notice NOT-ES-18-008 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-151 from the NIH Guide for Grants and Contracts

Notice NOT-DE-18-013 from the NIH Guide for Grants and Contracts

Notice NOT-DE-18-012 from the NIH Guide for Grants and Contracts

Notice NOT-AR-19-008 from the NIH Guide for Grants and Contracts

Notice NOT-AT-18-007 from the NIH Guide for Grants and Contracts

Notice NOT-HS-18-006 from the NIH Guide for Grants and Contracts

Notice NOT-FD-18-007 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-007 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-147 from the NIH Guide for Grants and Contracts

Notice NOT-DE-18-011 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-18-006 from the NIH Guide for Grants and Contracts. The intended outcome of this program is to advance efforts to improve and develop state drug residue prevention programs. It is necessary to provide assistance to state drug residue programs that need a stronger foundation to promote the prevention of illegal drug residues in animal derived foods through educational outreach and training. This program is intended to ensure drug residue prevention programs are developed to protect consumer exposure to drug residues in the edible products of food animals and support activities related to drug residue prevention. In addition, these awards will assist state agencies to better direct their programs to reduce the outcomes of illegal drug residues in animal derived foods. This cooperative agreement program (CAP) will focus on outreach, education and training. In addition, grantees will focus on performing targeted on-site assessments related to drug residue violations and best practice visits to industry and individuals to communicate proper drug use and promote effective management practices for drug residue prevention.

Notice NOT-OD-18-148 from the NIH Guide for Grants and Contracts